HOUSTON INNOVATORS PODCAST EPISODE 193

Serial entrepreneur launches new fund to support Houston's East End community development

Erik Ibarra's latest venture is to give agency to residents in the neighborhood he grew up in. Photo courtesy

Innovation isn't always tinkering with tech or programming software, although serial entrepreneur Erik Ibarra knows that world well. Sometimes it's about rethinking how a community improves and develops without doing the residents a disservice.

That's why Ibarra started Magnolia Fund, a mission-driven investment fund dedicated to enriching the East End community and preserving the neighborhood's culture and history. Ibarra, who has lived in the area the majority of his life, says on the Houston Innovators Podcast, that he's looking to turn residents into investors.

"Our investors from the neighborhood, today they walk around and look at their house and say, 'I own that,' and that's great," Ibarra says. "In the future, our investors should be able to say that, and then point to a building and say, 'I own a portion of that building too. And I helped that small business over there.'"

Ibarra explains that he's seen the East End area evolve a lot, and he wants to create a way to make sure residents are a part of that evolution and aren't being left behind in that process.

"Over the years, I've felt like there's so much development going on. But, the people from the neighborhood are very often just passive — they don't get a chance to benefit from or think about how they could participate in these new developments," Ibarra says. "The neighborhood is very close to my heart, and, about a year ago, I realized I wanted to do something about this."

The limited partners of the Magnolia Fund will contribute as investors, and then Ibarra and his team will identify a worthy development to take control of. As he explains, the vision for the property is "La Sala," a living room for the community, with an open area for communing, a kitchen incubator for food entrepreneurs, and an outdoor patio and stage for music and events.

While this is his first foray into the investor side of the equation, Ibarra has been an entrepreneur in Houston since the early 2000s. He's been an active mentor to startup founders, and has seen the ecosystem develop as he's started and grown his businesses.

He's currently the founder and CEO of ORDRS, a digital health platform for optimized lab testing founded in 2018. The company's B2B platform enables health care providers to better manage lab testing, and Ibarra says ORDRS saw a lot of growth during the pandemic. Something he's passionate about with this venture is the ability to provide better access and information about lab testing to patients.

"As a company we strive for transparency in health care," Ibarra says. "If we could provide instant access to a menu of tests for our customers, ... then hopefully our customers can pass those savings on to those customers. Access to testing is important. Access to the transparency in pricing is equally important."

Ibarra shares more about ORDRS, his role as a mentor, and his vision for the fund on the podcast. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted